Skip to main content

Fresenius Q2/22 Results

Q2/H1 2022 Results

Business development marked by significantly worsening headwinds at Fresenius Medical Care and increased macroeconomic challenges

 

  • Fresenius Medical Care Business development impacted by unprecedented U.S. labor market situation and worsening macroeconomic environment

  • Fresenius Kabi with solid organic sales growth despite tough prior-year-quarter

  • Fresenius Helios with continued good admissions growth in Germany and Spain

  • Fresenius Vamed still impacted by ongoing headwinds; service business supported by increasing elective treatment activity

  • Cost and efficiency program evolving according to plan

  • Starting date for Dr. Carla Kriwet as CEO of Fresenius Medical Care advanced to October 1, 2022

Selected Key Figures H1/2022

SALES

19738 m

+ 4% 1

H1/21: €18,230 m

EBIT 2

2003 m

-7% 1

H1/21: €2,042 m

NET INCOME 2, 3

913 m

-3% 1, 4

H1/21: €911 m

EARNINGS PER SHARE 2, 3

1.63 m

-4% 1

H1/21: €1.63

1 In constant currency

2 Before special items

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

4 Excluding Ivenix acquisition

Sales by business segment

€ in millions H1/22 H1/21 ChangeOrganic sales growthCurrency translation effectsAcquisitionsDivestitures% of total sales1

Fresenius Medical Care

9,3058,5309%1%7%1%0%47%

Fresenius Kabi

3,7433,5166%1%5%0%0%19%

Fresenius Helios

5,8565,3879%6%1%2%0%29%

Fresenius Vamed

1,0751,0334%4%1%0%-1%5%

Total

19,73818,2308%3%4%1%0%100%

  • 1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.

Archive